Screener
Protagonist Therapeutics PTGX Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Interest income | 6,429 | 7,406 | 12,305 | 14,979 |
| Other (expense) income, net | (81) | 36 | (28) | 118 |
| Income (loss) before income tax expense | 165,114 | (34,599) | 167,395 | (46,254) |
| Income tax expense | 2,265 | 172 | 763 | 172 |
| Net income (loss) | $162,849 | $(34,771) | $166,632 | $(46,426) |
| Net income (loss) per share, basic | $2.47 | $(0.55) | $2.54 | $(0.73) |
| Net income (loss) per share, diluted | $2.29 | $(0.55) | $2.35 | $(0.73) |
| Weighted-average shares used to compute net income (loss) per share, basic | 65,935,769 | 63,510,537 | 65,514,150 | 63,238,682 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's income tax?
- Protagonist Therapeutics (PTGX) reported income tax of $2.27M in Q2 2026.
- How has Protagonist Therapeutics's income tax changed year-over-year?
- Protagonist Therapeutics's income tax increased by 1216.9% year-over-year, from $172K to $2.27M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Protagonist Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude